Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MK-4280A + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-4280A | MK4280A|MK 4280A | Immune Checkpoint Inhibitor 146 LAG3 Antibody 18 PD-L1/PD-1 antibody 112 | Limited information is currently available on MK-4280A, a coformulation of MK-4280 and Pembrolizumab (Dec 2022). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05342636 | Phase Ib/II | Irinotecan + Pembrolizumab Irinotecan + MK-4830 + Pembrolizumab MK-4830 + Paclitaxel + Pembrolizumab Lenvatinib + MK-4830 + Pembrolizumab Irinotecan + MK-4280A MK-4280A + Paclitaxel Paclitaxel + Pembrolizumab | A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A) | Recruiting | ITA | FRA | DEU | 10 |